| Rank |
Status |
Study |
| 1 |
Not yet recruiting
|
Clinical Decision Support System for Quality Assurance in Potassium-Increasing Drug-Drug-Interactions
| Condition: |
Hyperkalemia |
| Intervention: |
Behavioral: decision support in potassium-inc. drug-drug-interactions |
| Outcome Measures: |
Impact on serum potassium monitoring during potassium-increasing drug-drug-interactions; Frequency of hyperkalemia during potassium-increasing drug-drug-interactions; Frequency of potassium-increasing drug-drug-interactions ordered in the presence of hyperkalemia; Frequency of transfers to the ICU during potassium-increasing drug-drug-interactions in function of the serum potassium level; Frequency of death during potassium-increasing drug-drug-interactions in the presence or absence of hyperkalemia; Change in frequency distribution of serum potassium monitoring intervals; Response of physicians to the computer-based alerts and reminders |
|
| 2 |
Recruiting
|
Efficacy of Sodium Polystyrene Sulfonate in the Treatment of Hyperkaliemia in Pre-dialysis Patients
| Conditions: |
Hyperkalemia; Chronic Kidney Failure |
| Interventions: |
Drug: Sodium polystyrene sulfonate; Drug: Lactose with carob gum |
| Outcome Measures: |
Change in serum potassium levels from baseline; Proportion of subjects attaining normokalemia (serum potassium level of 3.5 to 5.5 mmol/L) in each treatment arm; Number of patients with adverse events in each treatment group |
|
| 3 |
Recruiting
|
Safety & Efficacy of Zirconium Silicate Dosed for 28 Days in Hyperkalemia.
| Condition: |
Hyperkalemia |
| Interventions: |
Drug: Zirconium silicate (acute phase); Drug: Zirconium silicate (maintenance phase); Other: Silicilate microcrystaline cellulose (maintenance phase) |
| Outcome Measures: |
Maintenance of serum potassium level with once daily ZS for 28 days after establishment of normokalemia with ZS three times a day for first 48 hours.; Proportion of subjects who convert from hyperkalemia to normokalemia after 10g ZS three times a day. |
|
| 4 |
Recruiting
|
Open-label Dosing of ZS 10g qd for 60 Days to Extend Study ZS-004, Safety & Efficacy of ZS (Zirconium Silicate) in Hyperkalemia.
| Condition: |
Hyperkalemia |
| Intervention: |
Drug: Zirconium silicate |
| Outcome Measure: |
Maintenance of serum potassium within normal range (3.5 5.0 mmol/l) with once daily ZS for 2 months after establishment of normokalemia in prior ZS-004 study, or after an additional 48-hour treatment with 10g ZS three times daily. |
|
| 5 |
Unknown †
|
Genetic Determinants of the Hypokalemic and Hyperglycemic Effect of Albuterol Inhalation
| Conditions: |
Hyperkalemia; Chronic Renal Failure |
| Intervention: |
Drug: Albuterol (1,200 μg) through metered-dose inhaler |
| Outcome Measures: |
The extent of decrease in plasma potassium concentration; The extent of increase in plasma glucose concentration; Plasma concentration of albuterol |
|
| 6 |
Recruiting
|
Use of Spironolactone for the Prevention of Electrolyte Abnormalities in Patients Treated With Amphotericin B
| Condition: |
Patients With Indications for AmB Treatment |
| Interventions: |
Drug: Spironolactone 100mg; Drug: Spironolactone 200mg; Drug: Placebo |
| Outcome Measures: |
Incidence of hypokalemia ≤3.5mEq/L; Average potassium supplementation; Incidence of hyperkalemia; Acute kidney injury; Incidence of renal tubular damage; Incidence of hypomagnesemia |
|
| 7 |
Unknown †
|
Aldosterone in Diabetic Nephropathy
| Condition: |
Diabetic Nephropathy |
| Interventions: |
Drug: Spironolactone; Drug: Placebo |
| Outcome Measures: |
Reduction of albuminuria; Reduction of diastolic disfunction |
|
| 8 |
Recruiting
|
Attenuation of Cardiac Effects of Arteriovenous Fistula Creation With Losartan
| Conditions: |
Renal Failure; Left Ventricular Hypertrophy |
| Intervention: |
Drug: losartan |
| Outcome Measure: |
left ventricular hypertrophy |
|
| 9 |
Recruiting
|
Acetazolamide and Spironolactone to Increase Natriuresis in Congestive Heart Failure
| Condition: |
Heart Failure |
| Interventions: |
Drug: Combination therapy with acetazolamide and low-dose loop diuretics; Drug: High-dose loop diuretics; Drug: Upfront therapy with oral spironolactone |
| Outcome Measures: |
Acetazolamide arm: natriuresis 24 h; Spironolactone arm: incidence of hypo- (serum potassium <3.5 mmol/L) or hyperkalemia (serum potassium >5.0 mmol/L); NT-proBNP change after 72 h; Worsening renal function; Persistent renal impairment; Peak plasma aldosterone concentration after 72 h; Peak plasma renin activity after 72 h |
|
| 10 |
Not yet recruiting
|
L-Arginine and Spironolactone Trial in Dialysis-Dependent ESRD
| Conditions: |
End Stage Renal Disease; Hemodialysis |
| Interventions: |
Drug: Spironolactone; Dietary Supplement: L-arginine; Drug: Placebo |
| Outcome Measures: |
Change in coronary Flow Reserve (PET); Change in left ventricular diastolic function; Association between coronary flow reserve (CFR) and tissue doppler index (E'); Change in resting myocardial blood flow; Change in left ventricular mass index; Change in coronary vascular resistance; Association between change in coronary flow reserve (CFR) and change in diastolic function-tissue doppler index (E'); Change in early diastolic function (E'); Combined cardiovascular safety; Cardiovascular death; Hyperkalemia; Hypotension; Change in early coronary flow reserve; Change in hyperemic myocardial blood flow |
|
| 11 |
Recruiting
|
Clinical Study Of Eplerenone In Japanese Patients With Chronic Heart Failure
| Condition: |
Heart Failure |
| Interventions: |
Drug: Eplerenone; Drug: Placebo |
| Outcome Measures: |
First occurrence of cardiovascular mortality or heart failure hospitalization; First occurrence of Cardiovascular (CV) mortality, heart failure (HF) hospitalization or Addition/Increase of HF medication due to HF worsening; All-cause mortality; CV mortality; All-cause hospitalization; HF hospitalization; All-cause mortality or all-cause hospitalization; HF mortality or HF hospitalization; CV hospitalization; Addition/Increase of HF medication due to HF worsening; Fatal/non-fatal myocardial infarction; Fatal/non-fatal stroke; New onset atrial fibrillation/flutter; New onset diabetes mellitus; Worsening renal function (if it results in hospitalization); Hospitalization for hyperkalemia; Plasma BNP, Serum nt-BNP; LVEF; NYHA classification; Specific activity scale (SAS) |
|
| 12 |
Recruiting
|
Perioperative Insulin, GIK or GLP-1 Treatment in Diabetes Mellitus
| Condition: |
Diabetes Mellitus Type II |
| Interventions: |
Drug: Liraglutide; Drug: Insulin bolus; Drug: GIK infusion |
| Outcome Measures: |
Median glucose; Total Insulin administration; Postoperative complications; Hypoglycemia; Hypo- and hyperkalemia |
|
| 13 |
Unknown †
|
The Effect of Glucose-Insulin-Potassium Infusion in Patients Undergoing Cardiac Surgery
| Conditions: |
Aortic Stenosis; Coronary Heart Disease; Heart Failure |
| Interventions: |
Drug: Glucose-insulin-potassium; Drug: Placebo |
| Outcome Measures: |
Serum troponin and creatinine kinase; Systolic and diastolic cardiac function using transoesophageal echocardiography; Hypo-/hyperglycemia Hypo-/hyperkaliemia; Serious cardiovascular adverse events (myocardial infarction, cardiac arrhythmia, low cardiac output, stroke) |
|
| 14 |
Unknown †
|
Effect of Rapid Transfusion With Fluid Management System (FMS) on Plasma Potassium in Liver Transplantation Recipients
| Condition: |
Condition Requiring Rapid Transfusion During Liver Transplantation Surgery |
| Intervention: |
|
| Outcome Measures: |
potassium concentration in the Fluid Management System (FMS) reservoir; plasma potassium of the patient |
|
| 15 |
Recruiting
|
ALdosterone Antagonist Chronic HEModialysis Interventional Survival Trial
| Condition: |
End Stage Renal Failure on Dialysis |
| Interventions: |
Drug: Spironolactone; Drug: Placebo |
| Outcome Measures: |
The time to onset of the first incident :non-fatal MI or hospitalization for heart failure or nonfatal stroke or cardiovascular (CV) death; The cumulate rate of nonfatal MI, hospitalization for heart failure, nonfatal stroke or CV death; The time to onset of death from i) any cause and ii) from a CV event and iii) from a non CV cause; The time of survival without a major CV event (nonfatal MI, hospitalization for heart failure, non-fatal stroke, cardiac arrest resuscitation); Incidence of procedures related to stenosis or vascular access thrombosis for hemodialysis (HD); Incidence of coronary or peripheral revascularizations (including lower limb amputations); Blood pressure and its inter visit variability; The occurrence of atrial fibrillation; Incidence of hyperkalemia> 6 mmol/l; Estimation of the effect of treatment on quality of life. |
|
| 16 |
Not yet recruiting
|
Aliskiren Study of Safety and Efficacy in Senior Hypertensives
| Condition: |
Hypertension |
| Interventions: |
Drug: Aliskiren; Drug: Amlodipine; Drug: Ramipril; Drug: Hydrochlorothiazide |
| Outcome Measures: |
Change from baseline in mean sitting systolic blood pressure (MSSBP) to week 8; Number of patients with serious adverse events and adverse events; Number of patients with hyperkalemia, hypotension and reduction of estimated glomerular filtration rate (eGFR); Change from baseline in mean sitting systolic blood pressure (MSSBP) at the end of double blind period; Percentage of patients achieving blood pressure control; Percentage of patients with major cardiovascular events; Number of patients with gastrointestinal tract cancer |
|
| 17 |
Not yet recruiting
|
ATG Versus Basiliximab in Kidney Transplant Displaying Low Immunological Risk But High Susceptibility to DGF
| Condition: |
Kidney Transplantation |
| Interventions: |
Drug: Anti-Thymocyte Globulins treatment; Drug: Basiliximab treatment |
| Outcome Measures: |
Occurrence of a delayed graft function; Duration of the delayed graft function; Evolution of estimated glomerular filtration rate (eGFR); Number of dialysis procedures performed after transplantation without taking into account the dialysis due to hyperkaliemia and/or hyperhydratation; Evolution of Tacrolimus levels (T0) from Day 1 to Day 7 post transplantation then every 2 days until hospital discharge.; Hematologic effect within the first 3 months of surgery (WBC monitoring, CD3, CD4, CD8, CD19, NK and platelet sub population analysis).; Occurrence of infections within the first 3 months post transplantation, especially the CMV and BK reactivation assessed by RTPCR; Occurrence of biopsy-confirmed acute rejection episodes and subclinical acute rejection episodes within the first 3 months post transplantation.; Percentage of renal fibrosis on a surveillance kidney biopsy at 3 months post transplantation |
|
| 18 |
Recruiting
|
Spironolactone for Pulmonary Arterial Hypertension
| Condition: |
Pulmonary Arterial Hypertension |
| Interventions: |
Drug: Spironolactone; Drug: Placebo |
| Outcome Measures: |
Change in placebo corrected 6-minute walk distance; Clinical worsening; Change in placebo corrected VO2 max; Change in right ventricular function; Biomarkers of vascular inflammation; Rate of study drug discontinuation due to hyperkalemia, renal insufficiency, or other side effects such as breast pain and gynecomastia |
|
| 19 |
Recruiting
|
Genes, Fibrinolysis and Endothelial Dysfunction- Dialysis Aim 3
| Conditions: |
Oxidative Stress; Endothelial Dysfunction |
| Interventions: |
Drug: ramipril (ACE inhibitor); Drug: valsartan (ARB); Drug: Placebo |
| Outcome Measures: |
To compare the long term effects of ACE inhibition or angiotensin receptor blockade versus placebo on biomarkers of fibrinolysis, oxidative stress and inflammation in patients with chronic kidney disease undergoing maintenance hemodialysis; To compare the long term effects of ACE inhibition or AT1 receptor blockade versus placebo on carotid intima-media thickness (IMT) in patients with chronic kidney disease undergoing maintenance hemodialysis; Track safety endpoints- hyperkalemia, hypotension, nonfatal myocardial infarction, nonfatal stroke, death from cardiac causes, fatal stroke, death due to any cause. |
|
| 20 |
Recruiting
|
EPLErenone in CsA-Treated Recipients (EpleCsAT): Safety
| Conditions: |
Chronic Kidney Insufficiency; Kidney Transplantation |
| Intervention: |
Drug: Eplerenone |
| Outcome Measure: |
Occurence of an adverse event requiring the discontinuation of eplerenone |
|
